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Emerging dynamics of evidence and trust in online user-to-user engagement: the case of 
'unproven' stem cell therapies. 
 
Abstract: This article explores the ways in which patients and their families (hereafter referred as 
users) share and evaluate disease-specific evidence via online communities. The aim is to 
understand what this user engagement in healthcare and knowledge production reveals about 
society's shifting perceptions of trust in the institutions of 'evidence-based medicine' (EBM) such 
as regulators, bioethicists, and scientists and the implications for EBM. To do this, I use the case 
of experimental stem cell therapies (eSCTs). ESCTs are commonly labelled in academic literature 
as ‘unproven,’ a label that frames their lack of conclusive clinical evidence as unsafe, inefficacious 
and thus unethical when clinically used. Despite this framing, users engage with other users to 
share and evaluate all available evidence for themselves, including on-going clinical trial and 
experiential evidence to build trust for and undertake eSCTs. Increasingly, this user engagement 
with evidence takes place in online communities that range from user-created and user-run 
Facebook pages to user-to-user discussion forums on healthcare provider sites or blogs with little 
if any provider-input in conversations. In this paper, I draw on a sample of these user 
conversations to show the complex and unpredictable ways in which what counts as evidence 
and how trust is built for it are shifting. In so doing, I reflect on the shifting relations between 
the institutions of EBM and society for greater control over evidence. 
 
  
Introduction 
In 2012 and 2013, two large-scale surveys of healthcare trends in the US (by Pew Research and 
PricewaterhouseCoopers) attempted to quantify an emerging trend of online health information 
seeking among patients and their families; or what I call user-to-user engagement. The 
PricewaterhouseCoopers (2012) survey found that 32% of adults used social media to follow family or 
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friends’ experiences of illness and disease. Twenty nine percent of adults sought information 
related to other patients’ experiences with their disease and 24% viewed health-related videos or 
images posted online by patients. This article explores the dynamics of online user-to-user 
engagement in healthcare and knowledge production in the specific case of experimental stem 
cell therapies (eSCTs), for which a majority of patients and their families (hereafter referred to as 
'users') build trust for eSCTs through online communities. The aim is to help understand 
society's shifting perceptions of trust in the institutions of 'evidence-based medicine' (EBM), such 
as regulators, bioethicists, scientists, etc. (hereafter referred as 'providers') and the implications of 
these shifts for EBM. 
 
Since the 1980s, social scientists have focused increasing attention upon the relations between 
science and society in the wake of growing mistrust in scientific knowledge and expertise (Leach, 
Scoones, & Wynne, 2005; Putnam, 1993; Starr, 1982; Wynne, 2006). Critical scholarship 
challenged the ‘deficit model’ that informed efforts to engage publics; a model which assumed 
that mistrust was due to ignorance or a ‘deficit’ in knowledge rather than critical thinking and the 
co-existence of other ways of knowing (Wynne, 2006). Partly in response to this critique and to a 
combination of large-scale citizen mobilisations (e.g. surrounding HIV/AIDS research in the 
90s) and growing discursive engagement with "more traditional ways of knowing medicine" like 
experiential evidence (Djulbegovic, Guyatt, & Ashcroft, 2009), more participatory models of 
EBM integrating experiential evidence have since emerged and become widely practiced, 
particularly in downstream healthcare settings (Charles, Gafni, & Freeman, 2009; Miles & 
Mezzich, 2011; Tonelli, 2006). 
 
Against this backdrop, the Internet has generated novel possibilities for publics to engage with 
evidence and medicine. One such example is the emergence of online communities dedicated to 
sharing and evaluating the credibility of all available disease-specific evidence including scientific 
and experiential evidence. What do these spaces reveal about the relations between scientific 
evidence (from basic research and clinical trials), public trust and scientific evidence as a basis for 
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policy? This paper  presents societal engagement from Facebook pages and discussion forums 
surrounding the clinical use of eSCTs. These online spaces can be thought of as online 
communities in which users share and evaluate available evidence to build trust in eSCTs, 
alongside traditional provider-based sources of trust-building, such as physicians. For instance, 
disease-specific discussion forums attract users on the basis of shared (disease-specific) interests 
and help foster kinship and knowledge sharing (e.g., discussions on MS Society UK) (Wright & 
Street, 2007). Nevertheless, it is important to emphasize that online user-user engagement 
represents one increasingly relevant perspective,  and not the entirety of experiences and views.  
 
What is notable about these communities for our purposes is the absence of input from 
‘providers.’ I will show that, in a context where eSCT users are viewed as ignorant or gullible 
(Qiu, 2009), these online spaces can be read as productive sites of user empowerment in 
producing and evaluating evidence for user choice of eSCTs (Andreassen & Trondsen, 2010; 
Lupton, 2013). By drawing attention to communities that do not actually want to be ‘engaged’ by 
providers, this article offers the provocation that the logic of participation and inclusiveness in 
existing community and public engagement models may not have gone far enough. Through 
relating user activity in online user-to-user engagement, this article explores why and how people 
produce, evaluate and build trust for evidence. As I will show, users do not simply disfavour 
scientific evidence in favour of experiential evidence, but rather combine these and other sources 
of evidence in complex and unpredictable ways. This article, therefore, casts online communities 
as productive epistemic spaces (in the sense of Haas' (2001, p. 11579) epistemic actors with 
"agency in politics and policy formation"), which signal a shift in what counts as evidence and 
how trust is built for this evidence. 
 
 
Dynamics of user-to-user engagement 
Contemporary public engagement is intended to foster dialogue between policymakers and policy 
takers and to engender mutual trust. However, critical scholarship has suggested that engagement 
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practices have been and continue to be mere tokenistic gestures by providers inline with 
"fashion-following" political rhetoric, and thus largely ineffective in rebuilding public trust 
(Wynne, 2006, p. 217). Wynne, for instance, showed that expert policymakers were instead 
interested in downstream "instrumental concerns about impacts...[and how] these can be 
identified, and represented, adequately by scientific risk assessment" (Wynne, 2006 p. 218).  
 
In particular, in the context of emerging technologies, there is a long history of contestation over 
the rights of technology end-users, which has intensified in the last decade (for an exhaustive 
discussion, see Smith et al., 2017). Consider for instance the case of AIDS activism in the 1990’s, 
which highlighted this chasm in the understanding of end-users between provider’s imagination 
of a future user and users’ lived experiences (Epstein, 1996; Lambert, 2013). Recent scholarship 
has sought to bridge this chasm with 'user-centred' technology design based on user experiences 
instead of "edited renderings" of the image of the user to suit specific professional or 
technological uses (Hyysalo & Johnson, 2015; see e.g., 'human-centred design' in Bazzano, 
Martin, Hicks, Faughnan, & Murphy, 2017).  
 
In policymaking, the enactment of 'Right-to-Try' legislation nationally and across thirty-seven US 
states since 2014, which allow terminal patients the 'right to try' experimental treatments without 
seeking prior FDA approval (Brennan, 2017), highlights this increasing focus on technology end-
users. Nevertheless, ‘Right-to-Try’ laws remain at its heart an "access debate" (Dresser, 2015) 
even though they highlight tensions between expert and lay interpretations about the adequacy or 
accuracy of available evidence in private treatment choices (Pear & Kaplan, 2017). Thus, to what 
extent access based considerations in policy like the UK's Early Access to Medicines Scheme launched 
in December 2014 will translate to meaningful considerations of lived experiences in the 
evidence basis of EBM remains unclear (Facey, Boivin, Gracia, Hansen, Scalzo, Mossman, & 
Single, 2010; Greenlagh, Snow, Ryan, Rees, & Salisbury, 2015), although the case for a 
"compromise policy" integrating experiential evidence in policymaking is emerging (Matthews & 
Iltis, 2015). 
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At the same time, as the PricewaterhouseCoopers (2012) survey data presented in the introduction 
suggest, when it comes to disease-specific evidence and treatments, users are increasingly 
engaging with other users to seek and share lived experiences (hereafter also referred as 
'experiential evidence'). Moreover, this engagement is sought and fostered in user-to-user 
relationships with little or, no recourse to provider-side inputs (Lupton, 2013). To understand 
these dynamics of evidence and trust in emerging user-to-user engagement, the contestation 
between scientific and experiential evidence in eSCTs provides an excellent case study.  
 
Experimental stem cell therapies 
Except for a handful of SCTs approved for public marketing, most remain experimental (i.e., 
lacking conclusive evidence of clinical safety and efficacy) and unavailable to the Euro-American 
public through public healthcare providers like the UK NHS and the US Medicare. However, 
eSCTs have been and continue to be available in private clinics in the global south (Lau, Ogbogu, 
Taylor, Stafinski, Menon, & Caulfield, 2008) and increasingly in OECD countries (Turner & 
Knoepfler, 2016; Berger, Ahmad, Bansal, Kapoor, Sipp, & Rasko, 2016). Since the early-2000s, 
media coverage of  the immense potential of stem cells as a ‘miracle cure’ created public demand 
for eSCTs (Ramesh, 2005). The result was that Euro-American seekers of eSCTs not only started 
travelling beyond their home countries to access eSCTs but also, in the absence of clinical 
evidence, started to seek and share experiential evidence to evaluate the benefits of eSCTs for 
themselves. In turn, providers used the term 'unproven' to describe eSCTs, highlighting public 
access to them as unsafe and unethical based on their lack of conclusive clinical evidence of 
efficacy (ISSCR, 2013; Lau et. al, 2008; McLean, Stewart, & Kerridge, 2015).  
 
On the one hand, the effect of a negative label like ‘unproven’ instead of a label like 
'experimental' for experimental SCTs is that 'unproven' not only casts eSCT practitioners as 
charlatans but also frame users as ‘gullible' and lacking the capacity to make good health choices 
(Qiu, 2009) without provider intervention (Master & Resnik, 2011). Thus, the construct of 
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'unproven' not only assumes a moral high ground that presupposes scientific evidence as the only 
legitimate way of knowing therapeutic safety and efficacy but also public trust in its legitimacy. In 
this sense, 'unproven' frames public trust in eSCTs within the boundaries of scientific evidence 
and delegitimises those stepping beyond those boundaries when considering ‘other’ forms of 
evidence like user experiences (ISSCR, 2008).  
 
On the other hand, the agency of eSCT users who "bypass" warnings by the "institutions of stem 
cell science" is increasingly studied (Salter, Zhou, & Datta, 2015; p. 162; see also Chen & 
Gottweis, 2013; Lupton, 2013), particularly in studies of how users build trust for experiential 
evidence through online user-user communities (Bharadwaj, 2012,p 312; Foster, 2016; Kallinikos 
& Tempini, 2014; Rachul, 2011). For instance, Petersen, MacGregor, & Munsie (2016) used the 
lens of the televised experience of Kristy Cruise – an Australian patient who had travelled to 
Russia to undertake eSCT – to shed light on the increasingly important role of digital media in 
shaping hope-risk expectations among users. Perhaps more than anything else, Petersen et.al 
(2016) highlighted the disease-specific communities that form around similar concerns with 
evidence and which this paper explores to understand why and how these communities engage 
with each other, and increasingly through online environments (see e.g., Aubusson, 2014 in 
McLean et al., 2015). Indeed, Sharpe, DiPietro, Jacob, & Illes' (2016, p.441) finding that among 
"individuals interested in stem cell tourism ...internet was the most commonly cited source for 
information-seeking, ...[with most using] stem cell clinic websites [and] social media," emphasizes 
the need to understand the emerging dynamics of online user-user engagement. This paper 
extends this growing body of work to understand why and how users 'step-out' beyond the 
notion of 'unproven' to evaluate for themselves the credibility of both scientific and experiential 
evidence via online communities; evaluations of what 'experiential data' is shared, provide 
opportunities for future research. This paper also extends the surveys by Pew Research (Fox & 
Duggan, 2013) and PricewaterhouseCoopers (2012) by exploring why user-to-user sharing of disease-
specific evidence is happening and how it is building trust in certain kinds of evidence. As this 
form of engagement is increasingly mediated through online communal spaces like Facebook and 
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discussion forums, a sample of user-to-user conversations in these spaces are studied to answer 
these questions.  
 
 
Method  
Sampling and data collection 
In this study, I used two search methods to draw a sample of user conversations. First, using the 
online Facebook-page ranking tool Socialbakers.com which ranks pages by user visits, I ranked the 
most user-visited Facebook pages using the search term ‘stem cell therapies’i (referred to in data 
extracts below as File1). The search returned 61 Facebook-pages of which eight were chosen after 
excluding others based on exclusion criteria including fewer than five user-visits or content 
relating to non-medical applications such as cosmetic surgery. Of the selected eight Facebook-
pages, four were moderated and run by patients' families, three by eSCT clinics and one by a 
private medical tourism facilitator. Second, I took a disease-specific approach, focusing on the 
top three websites on Multiple Sclerosis (MS) (excluding provider websites offering eSCTs) that 
users see when they Google ‘stem cell therapies multiple sclerosis’ namely, the National Multiple 
Sclerosis Society (www.facebook.com/nationalmssociety; 358 of 818 posts; 2014-2016), the MS 
Society (www.mssociety.org.uk; 69 of 818 posts; 2011-2012), and The Niche (ipscell.com; 141 of 
818 posts; 2012-2016) (referred to in extracts below as Files 2, 3 and 4 respectively). MS was 
chosen based on Berger et.al.'s (2016, pp. 160–161) survey of the “top [30] conditions treated by 
all clinics and academic centres” worldwide for eSCTs. The final sample had 818 posts and 20 
testimonials drawn from eight Facebook pages and three websites between 2011 and 2016. 
 
This dual search method mimicked the search pattern typically employed by users as identified 
through informal conversations with eSCT-patients at a private clinic in Delhi, India. The logic 
of the searches was that, while the Facebook-search gave users an array of user-created and -run 
conversations relating to all conversations in SCTs, the disease-specific search provided disease-
specific information and conversations on provider-run sites. Moreover, this sample of Facebook 
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and discussion forums is appropriate for this research as both platforms allow users to engage 
with each other over the long term and forge communities (unlike e.g. Twitter's event-centric 
public engagement) and is consistent with Sharpe et.al’s (2016,p. 441) findings of online 
community engagement trends in eSCTs. Importantly, this search method is emblematic of the 
ways in which the geographies of these online communities map into the lived experiences of 
users who travel globally to access eSCTs unavailable at home. 
 
Analysis  
The qualitative data analysis software Atlas-ti was used to organise thematic coding of the sample. 
Codes were derived inductively from my thematic analysis and the broad themes that emerged 
included issues of trust, distrust, betrayal, sense of victimisation, risk awareness and 
rationalisation, knowledge gain (and its sources) and knowledge sharing. 
 
Ethics and limitations  
A key limitation was that the Google search (in the disease-specific approach) generated an 
abundance of data in excess of one million results, from which only the top three sites were 
studied. This means that other sites could have revealed data important for this research but 
could not be studied due to human cognitive and time constraints. Another limitation, as with 
any social-media research, was the possibility of data inaccuracies arising from (a) ‘exaggerated 
views’ posted online, (b) differences between online and 'real-world' behaviours enabled by 
"[user] anonymity" on the internet (Beninger, Fry, Jago, Lepps, Nass, & Silvester, 2014) and (c) 
distortion by fake user accounts. Large social networks including Facebook were already using 
dedicated staff and various fake-account detection tools like SybilsRankii  as far back as 2012 (Cao, 
Sirivianos, Yang, & Pregueiro, 2012), although their effectiveness remains questionable. To 
reduce fake-account distortion, the research used participant ‘views’, which were repeatedly 
reflected across the web pages/sites (greater 'n') at different times by different participants. 
Lastly, this research was limited to English-language content because social media analytics 
applications like socialbakers.com are algorithmically limited to English content. Interestingly, there 
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were no discernible language proficiency issues because a Google search conducted from a UK-
based IP address (in an English-speaking region) is designed to return English-centric results - 
which is limiting. However, reconfiguring Google to each linguistic-region of the world was 
unfeasible. As regards research ethics, informed consent was deemed unnecessary as (a) only 
material in the public domain were used and (b) usernames were anonymised (blanked) where 
direct quotes are used or where possible data was presented in aggregate or paraphrased in 
accordance with anonymity and 'no harm'-requirements (Markham & Buchannan, 2012).  
 
 
Why users step out beyond the boundaries of 'unproven' 
Conversations revealed that participants stepped beyond the boundaries of 'unproven' to evaluate 
the trustworthiness and credibility of evidence. Decisions to do so were tied to distrust in 
processes, actors, and institutions underpinning scientific evidence, especially those perceived to 
have commercial linkages, but did not extend to distrust in scientific evidence itself. Participants 
widely believed in the systemic collusion between 'big pharma' (perceived as dishonest) and 
regulators, in particular, the US Food and Drug Administration (FDA). The belief that the FDA 
– the "protector" of public interests – was colluding against them engendered distrust and a sense 
of betrayal by institutions of scientific evidence perceived to have significant conflicts of public-
private interests (File2, File4). Participants viewed themselves as victims of the profit-driven 
pharmaceutical industry, which, in collusion with regulators, were perceived to profit from the 
'sickness industry': 
 
 The FDA is just in the hip pocket of Big Pharma. Too many drugs [have] been put out as 
safe and later people are dying from them. As adults we should have a little more freedom 
to make our own health decisions (File4-January/2012). 
  
 ...big pharmaceutical companies won't allow a cure. Too much money to be made keeping 
people sick (File2-June/2016). 
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Prominent recalls of drugs which had been granted market authorisation by leading regulators 
such as the FDA, despite the clinical evidence on the contrary, was viewed by participants as 
instances of regulator-industry collusion against public interests. In stem cells, the Regenexiii-v-
FDA case – where the US courts' ruling in favour of FDA regulating autologous (patient's own) 
stem-cells like drugs led to state-public contestation (Eisenstein, 2016) - was viewed by 
participants as evidence of the FDA’s collusion with 'big-pharma' to control and thereby profit 
from the human body. As one participant summarised:    
 
 ...FDA is in bed with the Pharmaceutical, they have been for decades. They have approved 
thousands of ‘legal’ drugs on the market, which has resulted in millions of deaths around 
America, through prescription drugs. ...to say stem cells are drugs is a complete and utter 
nonsense, it is an organ transplant. It has NOTHING to do with FDA or being a drug. In 
fact the FDA have persistently tried to shut down all stem cell activities as it is threatening 
their playground of manufacturing hard drugs and keeping people sick, as opposed to 
treating them once and for all. Wake up people!!! (File4-January/2012). 
 
 Until FDA can figure out how to make money on this, people will suffer financially and in 
health! (File4-December/2013). 
 
The phrase 'FDA' appeared 35 times among 141 posts in response to the "Top 10 list of 
important, easy-to-understand facts for patients about stem cell treatments" written by a stem cell 
scientist on a popular stem-cell advisory blog (File4). Only five (of 35) times 'FDA' appeared was 
it alongside a positive view. This suggests that the erosion of trust from the perceived conflicts of 
interest around institutions that legitimise scientific evidence such as the FDA had motivated 
trust for therapies distrusted by those institutions. As one user noted: 
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          Just because it is "unproven" by FDA standards does not make it a scam. ...Everyone 
should do their homework and do what is best for themselves (File2-October/2015). 
 
Thus if the negative label of 'unproven' frames public trust in eSCTs within the boundaries of 
scientific evidence and delegitimises those stepping beyond them, then questioning that label (as 
in the quote above) reflect at the very least (a) cognisance among participants about other ways 
of knowing or 'proving' and (b) agency to evaluate who can(not) be trusted. Intuitively, that this 
evidence evaluation was conducted in online communities almost devoid of provider inputs, 
revealed user-distrust in most providers as self-serving rather than public-interest serving: 
 
 ...'experts' voiced the concern that so many people trusted you tube more that the CDC - 
FDA etc. That is the problem we don't trust officialdom. ...XXX's survey ...suggested only 
one percent of us trust officialdom (File3-December/2011). 
 
The result of this is a form of user-to-user engagement that is unlike traditional provider-user 
models of participation premised on providers sharing power with users. Indeed, participants 
extended and attributed their distrust of providers onto experts by insinuating their collusion 
with 'Big Pharma' through examples reflecting conflicts of interest; especially targeting experts 
highly active in calling for global regulatory strengthening against eSCTs. For instance, one 
participant accused the provider and site-owner of a popular discussion forum of such conflicts 
of interest: 
 
 Doing the work that you do, you are too sophisticated to be ignorant of the actions of 
the FDA in serving Big Pharma and Big Medicine at the expense of the patient. The only 
possible explanation for your statements is your collusion and/or your financial 
dependence. Your statements betray you. (File4-January/2012). 
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In sum, participants’ evaluations of evidence were shaped by distrust in the commitment of 
EBM’s institutions to protecting public interests, especially those individuals and institutions with 
private or commercial interests. This distrust followed from the reverse logic that if 'unproven' 
SCTs were demonised by 'untrustworthy' providers, then eSCT practitioners could not be in 
collusion with Big Pharma - and thus they were worthy of re-evaluation and possibly worthy of 
trust as well. A key part of this logic was to establish the untrustworthiness of some providers, 
and this was done by citing instances of provider-industry collusion, corruption among scientific 
insiders and by discrediting expert credentials with proof of conflicts of interest (File2, File4). 
This suggests that distrust in some providers motivated some participants to step beyond the 
provider-constructed definition of eSCTs to evaluate all available evidence for themselves. 
Notably, distrust in providers is not the only reason that motivates user choice of eSCTs but adds 
to a host of complex and diverse reasons like illness severity, access restrictions to treatments, 
etc. explored elsewhere (see, e.g., Salter, Zhou, & Datta, 2014). 
 
How users evaluate evidence  
Participants evaluated a range of available evidence, including physicians’ advice, experiential 
evidence and scientific literature. For instance, the discussion threads on The Niche and MS Society 
UK mentioned "published/publication/pub-med" 11 and 14 times respectively (File4 and File3). 
One participant offered the following sources (at times with hyperlinks) to help other 
participants to research treatment choices in Multiple Sclerosis (MS): 
 
 ...UK-NICE [guidance document]; Centonze etc. of University Hospital Tor Vergata 
(Rome); the Annals of Neurology, July 2011 (pub-med), MS Matters, Pub-Med (4 times), 
UK Parliament publications, Cochrane Summary and Monto et.al Report 2008 (IEP.org) 
(File3-October/2011). 
  
Apart from the scientific research articles discussed above, participants also expressed trust in 
publications by entities such as the Cochrane Collaboration,iv which provides reviews of diverse 
 13 
conditions based on aggregates of diverse evidence. Overall, participant comments revealed high 
degrees of trust in basic research papers and publications from sources perceived as trustworthy 
like UK Parliament papers and Cochrane Collaboration analyses. 
 
Participants were interested in educating themselves in the science of MS by extensively and 
exhaustively triangulating their knowledge through searching, monitoring, researching and at 
times following basic research study results (e.g. cohort studies) over years, often remarking: "...I 
have researched so much..." or "I have been researching this for a while and reading on 
everything I can" (File2-October/2015). One outcome of this was that discussion forums of 
large disease societies and patient organisations were used by users as knowledge repositories to 
share and learn about competing views, new research, on-going trial information, members’ 
disease progress (or recovery) and more. In turn, participants used this resource to evaluate 
media coverage of ‘unproven’ eSCTs. As one participant commented,  
 
 All too often new treatments are 'glamourised' - there is nothing easy or fool proof! 
(File2-October/2015).  
 
Some participants also expressed a preference for reading scientific findings informing media 
coverage (File3-October/2011). Thus suggesting critical evaluation of evidence amongst users 
that challenge assumptions of information deficit underlying 'gullible' user choices of eSCTs 
(Master & Resnik, 2011).  
 
Participants requested, shared and empathised with other users’ views, evaluations and disease 
experiences. The Facebook page of the National MS Society (USA) was one of the most frequently 
searched pages under the search term MS and contained 15 requests for information about 
eSCTs. Below is a typical solicitation for further information on discussion forums: 
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 Hello All, I have recently come across a treatment for MS - CCVSI. It is an operation, 
which unblocks veins to allow blood flow. It isn't available in the UK but can be done in 
Poland and some other countries. Has anyone else heard anything or had this 
treatment???? (File3-October/2011).  
 
The solicitation elicited 67 comments, including five comments about disease experiences and 
four  about ‘collusion between pharma and regulators.’ It also included 24 comments for and 26 
against experimental therapies. Thus, it was not the case that users only shared or heard 'positive' 
experiences. On the contrary, users had a high awareness of the risks of eSCTs and evaluated 
therapies based on individual risk-rationalisation calculus' typically combining low tolerance for 
'safety' risks with high preference for 'efficacy' risks as below, 
 
 I have been researching this for a while and reading on everything I can the death rate is 
less than 1% (Evaluating 'safety risks'; File2-October/2015).  
  
 ...the acceptable risk to the NHS is 1%, the risk so far for the CCSVI intervention is 
about 100 times lower than that. Some 30,000 people world wide have been treated, only 
three people have died and a handful have suffered some complications (Evaluating 
'efficacy risks'; File3-October/2011).  
 
Consequently, participants viewed eSCTs as a way of 'improving' quality of life while 'hoping' for 
cures. The discussion thread on National MS Society contained 32 (of 358) posts expressing hope 
and prayers for a future cure, 23 posts expecting stem cells to improve quality of life and zero 
comments indicating expectations of a cure from eSCTs. Similarly, while patients expressed trust 
in eSCTs and wanted others to trust in them, they were careful to convey realistic expectations:  
 
 Like anything else, HSCT doesn't work for 100% of patients, but it works for a very high 
percentage (File2-June/2015). 
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 What works for one doesn't for another. No two cases [are] alike as [X] said. ...Just don't 
 turn people off from something that may work wonders for them. (File2-
October/2015). 
 
Negative views or experiences were shared and viewed as important in participants’ evaluations 
of evidence. As one commented:  
   
 ...it doesn't work for everyone, and it certainly doesn't do the sort of things that you have 
a tendency to claim because people DO relapse and DO progress while on it; in fact 
some people get a lot worse (File3-December/2011). 
 
Users, in turn, suggested bolstering eSCTs with mainstream medication and wellness regimes for 
improved results: 
 
  "Every single person has to find their 'combo'. One size does not fit all... Genetic, 
vaccine, diet and environment play a part. ...It [i.e. HSCT] requires 35+ treatments to be 
effective. I was treating a frontal lobe brain injury, MS and migraines = gave me a new 
life!" (File2-June/2016). 
 
These conversations highlight the simplistic nature of the view that 'unproven' therapies victimise 
users who are thought to be gullible (Qiu, 2009) and lacking the capacity to make good health 
choices without provider intervention (Master & Resnik, 2011). Participants not only conducted 
exhaustive reviews of disease-specific evidence but made rationalisations of risks and benefits in 
their individual cases. Indeed, the finding that users access an array of information is consistent 
with Sharpe et al.’s (2016, p. 445) finding that users engage in "multi-level information-seeking." 
This, in turn, questions the provider presupposition that "the portrayal of stem cell medicine on 
provider websites [as] optimistic and unsubstantiated by peer-reviewed literature" may lead users 
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to make poor treatment choices (Lau et.al., 2008). For it assumes weak user decision-making 
processes mostly informed by and dependent on positive provider feedback without considering 
the complexity and array of sources that users reference.  
 
However, what is conspicuous by its absence (in the conversations analysed here) is the reference 
to provider-created public advisories warning users against undertaking eSCTs as well as 
academic papers by bioethicists or sociologists. This absence suggests that users rely on 
evaluating basic research evidence themselves or its interpretations by large credible bodies with 
public accountability (e.g. UK Parliament reports) and experiential data from other participants. 
Indeed, provider constructions of what constitutes 'evidence' (e.g., in provider-run online public 
advisories warning users against 'unproven' therapies) did not constitute a part of users’ evidence 
base (as shown in the previous section). This suggests that users appeared to have strong trust in 
basic research findings but not in provider constructed interpretations of its significance for 
them. At the same time, users placed a high value on experiential data shared in user-to-user 
settings when evaluating the trustworthiness of evidence for eSCTs. The latter is not surprising 
because studies show high degrees of trust in small-group 'community' settings when people 
know each other and where there are fewer chances of ‘free-ridership’ and ‘cheating’ (Artinger & 
Vulkan, 2016; Dietz et.al., 2003).  
 
Conclusion 
In this paper, I explored why and how people are evaluating 'evidence' themselves through online 
user-to-user engagement. First, I showed that users’ choice to evaluate evidence for themselves is 
grounded in deep distrust in some provider’s commitment to protecting public interests. The 
underlying logic is that if the untrustworthy institution's distrust 'unproven' therapies then eSCTs 
are at least worthy of evaluation and possibly worthy of trust as well. This trust for eSCTs also 
points towards the underlying logic of why user-to-user engagement excludes providers who are 
viewed as untrustworthy. Second, I showed that distrust in providers could not be conflated with 
distrust for scientific evidence. On the contrary, users demonstrated high levels of trust in (a) 
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basic research evidence (but not in provider constructed interpretation of its significance for 
them), and (b) experiential data shared between participants in user-to-user conversations. In 
effect, this article casts online user-to-user communities as productive epistemic spaces that are 
challenging the view propagated by providers that scientific evidence is the only legitimate form 
of knowing or 'proving' therapies. As I have shown, users combine abstract scientific evidence 
with lived experiences in complex and unpredictable ways. This shifting public perception of 
what counts as evidence and public trust for who says what counts as evidence not only calls for 
greater objectivity in presenting clinical evidence as one among many ways of knowing but also 
for greater user control over upstream evidence generation (Wynne, 2006; Lambert, 2013). 
 
That people trust people and rely on forming an opinion from a wide array of evidence as the 
data suggest, rather than blindly trust provider constructions of evidence, is evident. In turn, this 
highlights the shifting relations between the institutions of EBM and society, in which lay people 
are exerting greater control over the evidence that lies at the heart of evidence-based drug 
development policies. For if users are increasingly making their own evaluations of evidence with 
the result that they not only trust eSCTs but are accessing them by travelling beyond the 
jurisdiction of Euro-American policies that prevent and dissuade access to eSCTs, then for these 
users at least, these policies have little relevance. This implies that for providers to remain in 
touch with publics, there needs to be greater inclusiveness in the ways in which upstream 
institutions of EBM engage with users. 
 
 
------- 
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i  Search included substituting 'therapies' with 'treatments'. 
ii http://css.csail.mit.edu/6.858/2014/readings/sybilrank.pdf. 
iii US-based private clinic offering eSCTs for orthopaedic conditions. 
iv http://www.cochrane.org/CD009956/MS_exercise-therapy-fatigue-multiple-sclerosis  
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